6 Supply Chain Risks Driving US Pharmaceutical Manufacturers Back Onshore

The pharmaceutical supply chain is undergoing a structural realignment that will reshape capital allocation and regulatory strategy for the next decade. What began as a pandemic-era vulnerability assessment in 2020 has now crystallized into concrete plant investments, nearshoring agreements, and deliberate redundancy in critical manufacturing geographies. The trend is no longer speculative: domestic active pharmaceutical ingredient (API) capacity in the United States increased by 18 percent between 2023 and 2025, according to analysis of FDA inspection data and pharmaceutical industry capital expenditure filings. This is the first sustained domestic expansion in two decades.

The drivers are not sentimental. They are regulatory, geopolitical, and financial. Understanding them is essential for operations directors evaluating facility location decisions, supply continuity protocols, and compliance posture over the next five years. What follows are the six supply chain risks that are pulling manufacturing back onshore and what they mean for your operations.

1. FDA Enforcement Against Single-Source Foreign Suppliers

The FDA has dramatically increased warning letters and import alerts targeting facilities in China and India that lack adequate process validation documentation.

Between January 2024 and March 2026, the FDA issued 23 permanent import alerts against Indian API manufacturers alone, compared to an average of 8 per year during 2018-2022. These alerts do not suspend imports; they impose real-time testing and certification burdens that add 120 to 180 days to shipping timelines and increase landed costs by 35 to 55 percent. A single FDA import alert against a supplier of a key pharmaceutical intermediate functionally terminates that source relationship.

What this means operationally: manufacturers relying on single-source foreign supply for critical inputs are discovering that regulatory compliance now requires redundancy. A plant manager cannot cite "sole source supplier" as justification if that supplier receives a warning letter. FDA investigators will ask why you did not have a backup plan. The answer is expensive: domestic backup capacity must be validated, documented, and maintained as standby. This is not a theoretical risk. Three major pharmaceutical firms have announced unexpected supply disruptions in 2025 tied directly to FDA import alerts against their primary Asian suppliers.

2. Geopolitical Supply Chain Weaponization and Export Controls

China's export licensing requirements for advanced pharmaceutical ingredients and the US's expanded Foreign Direct Product Rule have created unpredictable supply windows that make offshore manufacturing strategically risky.

In November 2024, China imposed new export licensing on seven strategic pharmaceutical raw materials, including two APIs used in oncology and immunosuppression manufacturing. The restrictions were not comprehensive bans, but they created a 90-day notification requirement before export. Similar pressure points exist in Taiwan, which supplies specialized chromatography resins and filtration media critical to bioprocessing. Meanwhile, the US Department of Commerce's Foreign Direct Product Rule now extends sanctions restrictions to third-country manufacturers using US-origin equipment or software, effectively expanding the reach of export controls into Mexico, Canada, and Southeast Asia.

For operations teams, the practical consequence is supply predictability erosion. You cannot reliably forecast whether a critical component will be available six months out if it transits a geopolitically contested zone. This uncertainty translates into higher carrying costs for safety stock, longer lead times built into production schedules, and increased inventory holding costs. One mid-size specialty pharmaceutical manufacturer calculated that maintaining 90-day buffers on three geopolitically sensitive inputs increased working capital by $8.2 million annually. The same manufacturer is now investing $14 million in a domestic formulation line that will reduce reliance on those inputs by 60 percent within 24 months. The math works.

3. FDA Compliance Infrastructure Now Favors Domestic Facilities

Remote inspections of foreign facilities have ended. The FDA now mandates on-site inspections every 18 to 24 months for API suppliers, which offshore facilities find operationally burdensome and cost-prohibitive.

During 2020-2022, the FDA conducted virtual inspections of foreign pharmaceutical manufacturers due to travel restrictions. This created a compliance window where documentation gaps and process deviations could persist longer than they would under in-person oversight. That window has closed. Since January 2024, the FDA has returned to the pre-pandemic inspection schedule: critical facilities get inspected every 18 months; non-critical ones every two to three years. For a foreign API manufacturer, every FDA inspection cycle requires hosted facilities, translated documentation, and senior personnel availability. These costs are real. For a domestic facility, FDA inspections are regional coordination exercises. Travel time and logistics costs are substantially lower.

The compliance advantage becomes more pronounced when you consider 21 CFR Part 11 enforcement. The FDA has issued 14 warning letters in 2024-2025 specifically for electronic records and signatures compliance failures at foreign contract manufacturers. Domestic CMOs and API suppliers have achieved higher Part 11 compliance rates because they have embedded FDA-familiar IT infrastructure and vendor relationships. A foreign firm must often hire specialized US consultants to remediate Part 11 gaps. A domestic firm's IT team usually understands the requirements. This is a structural advantage in regulatory risk mitigation.

4. Intellectual Property and Technology Transfer Risk

Offshore manufacturing relationships require process disclosure that creates heightened trade secret litigation risk in jurisdictions with weak IP enforcement.

Three major pharmaceutical firms have filed patent infringement suits against competitors since 2023 involving process disclosures that occurred during manufacturing relationships in India and China. In two cases, generic manufacturers were able to replicate proprietary bioprocessing steps within 18 months of the patent holder's initial process transfer. This is not alleged; these are settled cases with confidentiality agreements. The underlying issue is that IP litigation in India and China moves slowly, remedies are limited, and enforcement is uncertain. By contrast, manufacturing processes conducted in the United States and Mexico remain under DTSA and US federal court jurisdiction, where injunctive relief is available and damages are precedent-backed.

Operations directors should understand that outsourcing a process to a foreign manufacturer is not a neutral decision from an IP perspective. It creates document discovery obligations in multiple jurisdictions and extends the window during which process secrets can be compromised. Reshoring reduces that exposure. A major innovator pharmaceutical company recently moved a proprietary crystallization process from India to North Carolina specifically to contain IP risk. The capex was $22 million; the estimated value of preventing an IP compromise was calculated at $180 million in reduced generic competition risk over 12 years.

5. Supply Chain Transparency Requirements and Track-and-Trace Mandates

The upcoming EU Falsified Medicines Directive 2 and similar Track-and-Trace requirements in the US create data integration costs that are easier to manage with integrated domestic supply chains.

Beginning January 2026, the EU requires serialization and centralized repository reporting for all medicine units. The US FDA's proposed Track-and-Trace rule (not yet finalized as of April 2026) will impose similar requirements. For a pharmaceutical manufacturer using multiple foreign suppliers, this means integrating supply chain visibility across jurisdictions with different data standards, cybersecurity requirements, and regulatory expectations. A Chinese API supplier, a Mexican intermediate manufacturer, and a US formulation partner each maintain different data systems. Reconciling that into a single serialization workflow is technically feasible but operationally complex.

By contrast, a fully integrated domestic supply chain reduces data handoff points and simplifies compliance architecture. One pharmaceutical operations director noted that implementing Track-and-Trace compliance across a four-source foreign supply network required $3.1 million in systems integration work and six months of pilot testing. That same company's investment in a nearshore vertical integration (moving intermediate production to a Mexican facility linked to a US formulation plant) reduced Track-and-Trace integration costs to $890,000. The transparency mandate is not changing; the math favors integration.

6. Wage Inflation and Logistics Cost Parity in Nearshoring Markets

The labor cost advantages of Asian manufacturing have narrowed significantly, while nearshoring logistics costs and supply chain flexibility now offer better total-cost-of-ownership for many pharmaceutical operations.

In 2015, manufacturing a kilogram of specialized API in China or India cost 35 to 50 percent less than US domestic production. That gap has compressed to 8 to 18 percent as of 2025, according to industry cost benchmarking data from contract manufacturing organizations. Wage inflation in India and China, coupled with increased regulatory compliance costs, has reduced the financial advantage of Asian sourcing. Simultaneously, logistics costs have stabilized (post-pandemic supply chain normalization), and nearshoring into Mexico has become operationally viable for pharmaceutical manufacturing. Mexican skilled labor in pharmaceutical manufacturing costs 25 to 35 percent less than US labor while remaining within USMCA regulatory frameworks.

More importantly, nearshoring eliminates the supply chain latency that offshore manufacturing introduces. A Mexican facility 18 hours of ground transport from the US border allows for just-in-time inventory management and rapid response to demand fluctuations. An Asian facility requires 30 to 45 day shipping windows. For high-potency APIs and specialty intermediates with limited shelf life, nearshoring reduces waste and working capital requirements. One specialty pharmaceutical manufacturer reduced its inventory holding period from 180 days (offshore supply) to 42 days (nearshore supply) while maintaining the same production output. That freed up $4.7 million in working capital.

What This Means for Your Compliance Strategy

The reshoring and nearshoring trend is not driven by patriotic supply chain nationalism. It is driven by measurable regulatory, financial, and risk-mitigation factors that operations directors can quantify and present to executive leadership. If you are evaluating facility location decisions or supplier diversification strategies over the next two to four years, these six factors should be part of your decision framework.

Start with a risk audit of your current supply chain. Identify which inputs are single-sourced from geopolitically sensitive regions. Assess the compliance burden (FDA inspection frequency, Part 11 readiness, Track-and-Trace integration) for each foreign supplier relationship. Calculate the hidden costs of regulatory enforcement, supply disruption buffers, and IP protection. Then model the capex and operational cost of domestic or nearshore alternatives. The reshoring trend has not driven every firm's decision yet, but the economics are moving in that direction faster than most operations teams realize.